Neurohormones, cytokines and programmed cell death in heart failure: A new paradigm for the remodeling heart

Cardiovascular Drugs and Therapy

Volumn 15, Issue 6, 2001, Pages 529-537

  Valgimigli, Marco ^a   Curello, Salvatore ^b   Ceconi, Claudio ^b   Agnoletti, Laura ^c   Comini, Laura ^c   Bachetti, Tiziana ^c   Merli, Elisa ^a   Ferrari, Roberto ^a,c  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c IRCCS   (Italy)

Author keywords

Angiotensin II; Atrial apoptosis; Cytokines; Heart failure; Neurohormones; TNF alfa

Indexed keywords

ANGIOTENSIN; CATECHOLAMINE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN 1; INTERLEUKIN 1; INTERLEUKIN 6; NEUROHORMONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CONFERENCE PAPER; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL;

ACETYLCHOLINESTERASE; ANGIOTENSINS; APOPTOSIS; CYTOKINES; ENDOTHELINS; HEART; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MYOCARDIAL INFARCTION; MYOCARDIUM; NEUROTRANSMITTER AGENTS; SYMPATHETIC NERVOUS SYSTEM; VENTRICULAR REMODELING;

EID: 0035712258     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1013771805743     Document Type: Conference Paper

References (87)

1. For the Task Force on heart failure of the European Society of Cardiology. Guidelines for the diagnosis of heart failure
2. Task Force report. Guidelines for the evaluation and management of heart failure
3. The effects of Digoxin on mortality and morbidity in patients with heart failure
4. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial
5. Beta-adrenergic blockade in chronic heart failure: Principles, progress and practice
6. Clinical effects of beta-adrenergic blockade in chronic heart failure
7. The effect of spitonactone on morbidity and mortality in patients with severe cardiac heart failure
8. Expansion of acute myocardial infarction: An experimental study
9. Patterns of the left ventricle dilatation during the six months after myocardial infarction
10. Remodeling and reparation of the cardiovascular system
11. Fibrillar collagen and remodeling of dilated canine left ventricle
12. Effect of captopril and enalapril on left ventricular geometry, function and collagen during healing after anterior and inferior myocardial infarction in a dog model
13. Global cardiac remodeling after acute myocardial infarction: A study in the rat model
14. Nonparallel changes in global left ventricular chamber volume and muscle mass during the first year after transmural myocardial infraction in humans
15. Cellular basis of ventricular remodeling after myocardial infarction
16. Left ventricular remodeling after myocardial infarction: A corollary to infarct expansion
17. Expansion versus extension: Two different complications of acute myocardial infarction
18. Direct extraction and estimation of collagenase(s) activity by zymograph in microquantities of rat myocardium and uterus
19. Left ventricular remodeling after myocardial infarction: A corollary to infarct expansion
20. Cadiac remodeling - Concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling behalf of an international forum on cardiac remodeling
21. Regional cardiac dilatation after acute myocardial infarction: Recognition by two dimensional echocardiography
22. Histopatological types of cardiac fibrosis in myocardial disease
23. Vetricular remodeling
24. Left ventricular hypertrophy: An initial response to myocardial injury
25. Isozyme pattern and activity of myocardial creative phosphokinase under heart adaptation to chronic overload
26. Ventricular remodeling: Consequences and therapy
27. Structural analysis of cat right ventricular pressure versus volume overload hypertrophy
28. Modulation of cardiac genes by mechanical stress: The oncogene signalling hypothesis
29. Growth and hypertrophy of the heart: Towards an understanding of cardiac-specific and inducible gene expression
30. ANG II receptors, c-myc and c-jun in myocytes after myocardial infarction and ventricular failure
31. Structural basis for pathological left ventricular hypertrophy
32. Cardiocyte adaptation to chronically altered load
33. Biochemical mechanisms of cardiac hypertrophy
34. New perspectives on left ventricular hypertrophy: Anatomy, physiology, and significance
35. The myocardial interstitium: Its structure and its role in ionic exchange
36. Myocardial collagen matrix remodeling in arterial hypertension
37. Ventricular remodeling after myocardial infarction
38. Effect of angiotens in II and antagonist saralasin on cell growth and renin in 3T3 and SV 373 cells
39. Prospects for cardioreparation
40. Cardiac hypertrophy in mice occurs in the absence of angiotensin receptors
41. Pathological hypertrophy and the cardiac interstitium: Fibrosis and the renin-angiotensin-aldosterone system
42. Endothelin: Visualization of mRNAs by in situ hybridization provides evidence for local action
43. Bioenergetic consequences of left ventricular remodeling
44. Growth factors, growth factor response elements and the cardiac phenotype
45. Regulation of cardiac gene expression during myocardial growth and hypertrophy: Molecular studies of an adaptive physiologic response
46. Deficient production of cyclic AMP: Pharmacologic evidence of an important cause of contractile dysfunction in patients with endstage heart failure
47. Effects of cardiac failure in rats on myocardial concentrations of noradrenaline and on atrial ANP: Bombesin- and neurotensin-like immunoreactivity
48. Decreased cathecolamines sensitivity and beta-adrenergic receptor density in failing human hearts
49. Myocardial cathecolamines and the pathophysiology of heart failure
50. Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by cathecolamines
51. Cardiac myocyte hypertrophy is associated with c-myc protooncogene expression
52. Myocardial hypertrophy produced by chronic infusion of subhypertensive doses of norepinephrine in the dos
53. Regression of myocardial hypertrophy and influence of the adrenergic system
54. Adrenergic effects on the biology of the adult mammalian cardiocyte
55. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is a alpha I adrenergic response
56. Hemodynamic versus adrenergic control of the cat right ventricular hypertrophy
57. Elevated circulating levels of tumor necrosis factor in congestive heart failure
58. Icreased concentration of tumor necrosis factor in "cachetic" patients with severe chronic heart failure
59. Tumor necrosis factor α in severe congestive heart failure
60. Pathophysiological correlates of increased serum tumor necrosisi factor in patients with congestive heart failure: Relation to nitric oxide-dependent vasodilation in the forearm circulation
61. Increased circulating cytokines in patients with myocarditis and cardiomyopathy
62. Increased levels of serum neopterin and decreased production of neutrophil superoxide anions in chronic heart failure with elevated levels of tumor necrosis facto-alpha
63. Neutralization of endogenous tumor necrosis factor ameliorates the severity of myosin-induced myocarditis
64. Tumor necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy
65. Expression of tumor necrosis factor in human cardiac rejection: An immunohistochemical and immunoblotting study
66. Circulating tumor necrosisi factor α (cachetin) in myocardial infarction
67. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass
68. Through thick and thin: Wasting, obesity and TNF-α
69. Two tumor necrosis factor receptors: Structure and function
70. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart
71. Interleukin-1 beta inhibits phospholamban gene expression in cultured cardiomyocytes
72. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness
73. Proinflammatory cytokines regulate tissue inhibitors of the metalloproteinases and disintegrin metalloproteinase in cardiac cells
74. Tumor necrosis facto-alpha provokes a hypertrophic growth response in adult cardiac myocytes
75. Divergent signaling via APO-1/FAS and the TNF receptor, two homologous molecules involved in physiological cell death
76. TNF-induced intracellular signalling leading to gene induction or to cytotoxicity by necrosis or by apoptosis
77. Serum from patients with severe heart failure downregulates eNOS and is proapoptotic. Role of tumor necrosis facto-alpha
78. Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure
79. Induction of apoptosis in fibroblasts by c-myc protein
80. Continuous c-fos expression precedes programmed cell death in vivo
81. The control of apoptosis in mammalian cells
82. Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rats
83. Loss of a gap 130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress
84. Isolated myocyte contractile function is normal in postinfarct remodeled rat heart with systolic dysfunction
85. Perperfusion injury induces apoptosis in rabbit cardiomyocytes
86. Cell death: The significance of apoptosis
87. Programmed cell death: Apoptosis and cardiovascular disease